#153356

Extracellular signal-related protein kinase 5 ERK5 Small Molecule (Collaborative Toolkit)

Cat. #153356

Extracellular signal-related protein kinase 5 ERK5 Small Molecule (Collaborative Toolkit)

Cat. #: 153356

Sub-type: Inhibitor

Availability: Please enquire for quantities and pricing

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Steve Wedge

Tool Details
Handling
Target Details
Application Details

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: Extracellular signal-related protein kinase 5 ERK5 Small Molecule (Collaborative Toolkit)
  • Cancers detailed: Breast cancer;Prostate;Hepatic
  • Tool sub type: Inhibitor
  • Primary target: ERK5
  • Description: An inhibitor of extracellular signal-related protein kinase 5 (ERK5). Mitogen/extracellular signal regulated kinase kinase-5 (MEK5) specifically activates ERK5, also known as Big MAP kinase 1 (BMK1). The MEK5/ERK5 pathway is activated by EGF and is required for EGF-induced proliferation and connexin 43 gap junction communication in certain cellular contexts. ERK5 is comprised of 815 amino acids with a unique C-terminal tail containing a myocyte enhancer factor 2 (MEF2)-interacting domain and a potent transcriptional activation domain. ERK5 regulates several transcriptional factors such as MEF2C, c-Fos, Fra-1, Sap-1, cMyc and NFÎşB. ERK5 activation has a potential role in tumorigenesis and is implicated in breast, prostate and hepatic cancer. ERK5 also plays a key role in embryogenesis; ERK5 knock-out embryos die between day 9.5 and 11.5 due to a loss of vascular integrity.
  • Purpose: Inhibitor
  • Selectivity: Tested in the DiscoveRx panel of 456 kinases at a concentration of 10 ÎźM. Seventeen kinases were inhibited by >99% at this concentration, including ERK5, and the S(35) selectivity score ((number of non-mutant kinases with % of control <35)/(number of non-mutant kinases tested)) was 0.205. Ten representative kinases were selected for Kd determinations and the three most sensitive kinases were CSF1R (46nM), DCAMKL1 (61 nM) and ERK5 (180 nM).
  • Molecular weight: A potent inhibitor of ERK5 in enzyme (IC50 = 79 nM) and whole cell (IC50 =970 nM) assays.
  • Solubility: 100ÎźM
  • Additional notes: Tested in vitro and in vivo.

Handling

  • Purity: 381 kDa

Target Details

  • Primary target: ERK5
  • Ic50: A potent inhibitor of ERK5 in enzyme (IC50 = 79 nM) and whole cell (IC50 =970 nM) assays.

Application Details

  • Application notes: Tested in vitro and in vivo. Cell permeability: Caco2 Papp A2B/B2A (Efflux ratio) = 27/26 (0.94)

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.